[Osteoprotegerin and fibroblast growth factor 23 in the development of cardiovascular events in chronic kidney disease].

@article{Dzgoeva2014OsteoprotegerinAF,
  title={[Osteoprotegerin and fibroblast growth factor 23 in the development of cardiovascular events in chronic kidney disease].},
  author={F. U. Dzgoeva and T. M. Gatagonova and T L Bestaeva and M Iu Sopoev and B G Bazaeva and O V Khamitsaeva},
  journal={Terapevticheskii arkhiv},
  year={2014},
  volume={86 6},
  pages={63-9}
}
AIM To study the role of the bone mineral metabolic mediators osteoprotegerin (OPG) and fibroblast growth factor 23 (FGF-23) in the mechanisms of cardiovascular events (CVEs) in chronic kidney disease (CKD). SUBJECTS AND METHODS Sixty-eight patients (30 men and 38 women) aged 38 to 64 years (mean age 49 +/- 6.3 years) with Stages III-VD CKD were examined. The stages of CKD were determined in accordance with the NKF-K/DOQI guidelines; glomerular filtration rate was calculated using the CKD-EPI… CONTINUE READING